ACIU
AC Immune SA
Stock NASDAQ – Stock Market Prices, News & Analysis
Biopharmaceutical company developing therapies for neurodegenerative diseases, including therapeutic vaccines for Alzheimer's disease.
AC Immune SA
ACIU
Biopharmaceutical company developing therapies for neurodegenerative diseases, including therapeutic vaccines for Alzheimer's disease.
Price history of AC Immune SA
Price history of AC Immune SA
Performance & Momentum
Strategic Analysis
AC Immune SA • 2026
AC Immune SA specializes in the development of innovative therapies for neurodegenerative diseases, with a distinguishing focus on therapeutic vaccines for Alzheimer's disease. Its positioning within Swiss biotechnology lends it scientific credibility in a sector characterized by high complexity and disruptive potential.
- Deep expertise in immunotherapies targeting neurodegenerative diseases
- Product portfolio centered on a critical medical issue on a global scale
- Innovative positioning around therapeutic vaccines, a relatively uncluttered niche
- History of volatile valuation and uncertain long-term returns on investment
- Dependence on clinical results and regulatory phases
The stock shows a clearly supported average momentum, reflecting a recent positive market dynamic around clinical advancements. This trend calls for cautious vigilance, combining short-term valuation opportunities with the usual inherent risks of the biotech sector.
Similar stocks to AC Immune SA
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
